Literature DB >> 34021842

Risk assessment model for heart failure in Chinese patients with Takayasu's arteritis.

Yu-Jiao Wang1, Li-Li Ma1,2, Yun Liu1, Yan Yan1, Ying Sun1, Yong-Shi Wang3, Xiao-Min Dai1, Zong-Fei Ji1, Ling-Ying Ma1, Hui-Yong Chen1, Lin-Di Jiang4,5.   

Abstract

OBJECTIVES: We aimed to construct and validate a risk assessment model to identify risk factors for heart failure (HF) in patients with Takayasu's arteritis (TAK).
METHODS: Three hundred sixty-five patients with TAK were recruited in the East China Takayasu Arteritis Cohort from January 2012 to December 2019. Patients were assigned into training and validation sets following a 2:1 ratio according to the date of enrollment. Clinical characteristics were compared between heart failure (HF) and non-HF subgroups in the training set, and a risk assessment model for HF and its scoring algorithm was established based on logistic regression, which was tested in the validation set.
RESULTS: Among total of 74 (20.27%) TAK patients exhibited HF, and 55 cases (74.32%) were in the training set. The risk factors for HF of TAK patients included onset age >38 years, serum tumor necrosis factor (TNF)-α concentration >10 pg/ml, aortic valve involvement, coronary artery involvement, and pulmonary hypertension. We constructed the model without TNF-α (Model 1) and with TNF-α (Model 2). Patients in the training set with the score ≥ 3 appeared to be associated with an increased risk of HF with an area under curve (AUC) of 0.88 and 0.90 in Model 1 and Model 2 respectively. The AUC reached to 0.88 and 0.89 in the validation set that proved the accuracy of the model.
CONCLUSIONS: We presented a risk assessment model of HF in TAK, which may help clinicians alert the complication of HF in the patients with specifically cardiac impairments. Key Points • Heart failure was not rare in Chinese Takayasu's arteritis patients, and there were approximately 20% of patients with heart failure in ECTA cohort. • Cardiac involvements on echocardiography include pathological valvular and atrioventricular abnormalities. • The onset age >38 years, serum tumor necrosis factor (TNF)-α concentration >10 pg/ml, aortic valve involvement, coronary artery involvement, and pulmonary hypertension were risk factors for heart failure in Takayasu's arteritis patients. • We constructed the model without TNF-α (Model 1) and with TNF-α (Model 2). Patients with the risk assessment model score of ≥ 3 appeared to be associated with an increased risk of heart failure.

Entities:  

Keywords:  Heart failure; Risk; Takayasu’s arteritis

Year:  2021        PMID: 34021842     DOI: 10.1007/s10067-021-05745-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  4 in total

1.  Effects of ET-1 and TNF-α levels on the cardiac function and prognosis in rats with chronic heart failure.

Authors:  J Tang; Q Xie; D Ma; W Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-12       Impact factor: 3.507

2.  Clinical Characteristics of Heart Involvement in Chinese Patients with Takayasu Arteritis.

Authors:  Jing Li; Hongchao Li; Fei Sun; Zhe Chen; Yunjiao Yang; Jiuliang Zhao; Mengtao Li; Xinping Tian; Xiaofeng Zeng
Journal:  J Rheumatol       Date:  2017-08-15       Impact factor: 4.666

3.  Ten-year Investigation of Clinical, Laboratory and Radiologic Manifestations and Complications in Patients with Takayasu's Arteritis in Three University Hospitals.

Authors:  Dalili Nooshin; Pazhouhi Neda; Samangooyi Shahdokht; Jamalian Ali
Journal:  Malays J Med Sci       Date:  2013-05

4.  A Case of Severe Advanced Takayasu Arteritis with Acute Myocardial Infarction as First Manifestation.

Authors:  A R Mihailovici; I Donoiu; O Istrătoaie; G C Târtea; A Bucșa
Journal:  Curr Health Sci J       Date:  2018-01-29
  4 in total
  1 in total

1.  Lung involvement prevalence in patients with early rheumatoid arthritis without known pulmonary disease: a multicentric cross sectional study.

Authors:  Francisco Paulin; Anastasia Secco; Federico Benavidez; Juan José Rodríguez Moncalvo; Orlando Gabriel Carballo; Fernanda Ingenito; Martin Eduardo Fernández; Agustina Cáceres; Fabian Caro; Patricia Sasaki; María Laura Alberti; Paola Orausclio; Augusto Riopedre; Santiago Rossi; María Celina de la Vega
Journal:  Adv Rheumatol       Date:  2021-08-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.